Trial record 1 of 1 for:
calgb30610
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
This study is currently recruiting participants.
(see Contacts and Locations)
Verified June 2016 by Alliance for Clinical Trials in Oncology
Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT00632853
First received: March 8, 2008
Last updated: June 24, 2016
Last verified: June 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Lung Cancer |
Radiation: Standard Radiation Dose Therapy Drug: cisplatin Drug: etoposide Radiation: High Radiation Dose Therapy Drug: carboplatin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
Resource links provided by NLM:
Further study details as provided by Alliance for Clinical Trials in Oncology:
Primary Outcome Measures:
- Overall survival time between 3 treatment arms [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Complete and partial response rates [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
- Failure-free survival [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 729 |
| Study Start Date: | March 2008 |
| Estimated Primary Completion Date: | June 2023 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Arm A - Standard Radiotherapy + Chemotherapy
Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):
|
Radiation: Standard Radiation Dose Therapy
45 Gy
Drug: cisplatin
IV
Drug: etoposide
IV
Drug: carboplatin
IV
|
|
Experimental: Arm B - High Dose Radiotherapy + Chemotherapy
Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):
|
Drug: cisplatin
IV
Drug: etoposide
IV
Radiation: High Radiation Dose Therapy
70 Gy
Drug: carboplatin
IV
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
-
Documentation of Disease
- Histologically or cytologically documented small cell lung cancer (SCLC)
-
Limited-stage disease patients with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes
- Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible
- Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not are not eligible unless they have a negative thoracentesis
- Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray are not eligible
- Measurable disease - Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2 cm with conventional techniques OR ≥ 1 cm by spiral CT scan
-
Prior Treatment
- Patients may have received one and only one cycle of chemotherapy prior to enrolling on CALGB 30610, which must have included carboplatin or cisplatin and etoposide.
- If a patient has had one cycle of cisplatin or carboplatin/etoposide prior to registration, the patient must have had all of it prior to registration tests as outlined in the protocol and prior to starting their first cycle of chemotherapy.
- Additionally, these patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy.
- Registration to CALGB 30610 must take place within 14-21 days after the start of the non-protocol therapy.
- Failing to do all of the above will make the patient NOT eligible for CALGB 30610.
- No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for SCLC
- No prior mediastinal or thoracic radiotherapy
- Patients with complete surgical resection of disease are not eligible
- Age Requirement ≥ 18 years of age
- ECOG Performance Status 0-2
- Non-pregnant and non-nursing - No patients that are known to be pregnant or nursing
-
Required Initial Laboratory Values
- Granulocytes ≥ 1,500/µl
- Platelet count ≥ 100,000/µl
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST (SGOT) ≤ 2.0 times ULN
- Serum creatinine ≤ 1.5 times ULN OR Calculated creatinine clearance ≥ 70 mL/min
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00632853
Show 225 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00632853
Contacts
| Contact: Jeffrey A. Bogart, MD | 315 464-5276 |
Show 225 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Investigators
| Study Chair: | Jeffrey A. Bogart, MD | State University of New York - Upstate Medical University |
More Information
Additional Information:
| Responsible Party: | Alliance for Clinical Trials in Oncology |
| ClinicalTrials.gov Identifier: | NCT00632853 History of Changes |
| Other Study ID Numbers: | CALGB-30610 CALGB-30610 RTOG 0538 U10CA031946 CDR0000588879 |
| Study First Received: | March 8, 2008 |
| Last Updated: | June 24, 2016 |
| Health Authority: | United States: Food and Drug Administration United States: NCI Central Institutional Review Board |
Keywords provided by Alliance for Clinical Trials in Oncology:
|
limited stage small cell lung cancer |
Additional relevant MeSH terms:
|
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Etoposide phosphate Cisplatin Carboplatin Etoposide Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on September 28, 2016